Literature DB >> 8990520

Identification of talinolol metabolites in urine of man, dog, rat and mouse after oral administration by high-performance liquid chromatography-thermospray tandem mass spectrometry.

H Schupke1, R Hempel, R Eckardt, T Kronbach.   

Abstract

A new specific HPLC-TSP-MS/MS assay for identification of beta-blocking drug talinolol and its metabolites in urinary samples of man, dog, rat and mouse after single oral administration has been developed. Centrifuged urines were directly injected into the HPLC-TSP-MS system. Based on thermospray MS/MS studies of 10 reference compounds, several selective CID-MS/MS reactions were found, which were typical of substructure elements of potential phase I metabolites. In this way the differentiation of various stereochemical positions of the hydroxyl group in the cyclohexyl ring moiety of metabolites was possible. Renal metabolic profiles for all investigated species were generated by HPLC-multiple reaction monitoring (MRM). The detected metabolites were characterized by TSP full scan and MS/MS analysis in relation to synthesized reference compounds. The major metabolic pathway in all species results in the hydroxylation of the cyclohexylring moiety of talinolol. In dog urine, a phase II metabolite, the O-glucuronide of talinolol (I) was found. In order to identify this structure, the use of electrospray ionization was also necessary.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8990520     DOI: 10.1002/(SICI)1096-9888(199612)31:12<1371::AID-JMS433>3.0.CO;2-4

Source DB:  PubMed          Journal:  J Mass Spectrom        ISSN: 1076-5174            Impact factor:   1.982


  3 in total

1.  Structural elucidation by electrospray mass spectrometry: an approach to the in vitro metabolism of the macrolide immunosuppressant SDZ RAD.

Authors:  C Vidal; G I Kirchner; K F Sewing
Journal:  J Am Soc Mass Spectrom       Date:  1998-12       Impact factor: 3.109

2.  Physiologically-based modelling in mice suggests an aggravated loss of clearance capacity after toxic liver damage.

Authors:  Arne Schenk; Ahmed Ghallab; Ute Hofmann; Reham Hassan; Michael Schwarz; Andreas Schuppert; Lars Ole Schwen; Albert Braeuning; Donato Teutonico; Jan G Hengstler; Lars Kuepfer
Journal:  Sci Rep       Date:  2017-07-24       Impact factor: 4.379

Review 3.  Advances in Proteomic Technologies and Its Contribution to the Field of Cancer.

Authors:  Mehdi Mesri
Journal:  Adv Med       Date:  2014-09-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.